Evidence map›Paper›PMID 30700954›Full record

ArticleEthiopian journal of health sciences2019

Is Albumin-based Resuscitation in Severe Sepsis and Septic Shock Justifiable? An Evidence from a Cost-effectiveness Evaluation.

Bereket Tigabu, Majid Davari, Abbas Kebriaeezadeh, Mojtaba Mojtahedzadeh, Kourosh Sadeghi, Zahra Jahangard-Rafsanjani

Open access · diamondAbstract read
In one paragraph

Article in Ethiopian journal of health sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 4 countries.

Bereket TigabuDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, International Campus, TUMS, Tehran, Iran.
Majid DavariDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, International Campus, TUMS, Tehran, Iran.
Abbas KebriaeezadehDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, International Campus, TUMS, Tehran, Iran.
Mojtaba MojtahedzadehDepartment of Clinical Pharmacy, Faculty of Pharmacy, TUMS, Tehran, Iran.
Kourosh SadeghiDepartment of Clinical Pharmacy, Faculty of Pharmacy, TUMS, Tehran, Iran.
Zahra Jahangard-RafsanjaniDepartment of Clinical Pharmacy, Faculty of Pharmacy, TUMS, Tehran, Iran.
Tehran University of Medical Sciences · IRSina Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFluid and antimicrobial therapy are the essential parts of sepsis management. The type of fluid to resuscitate with is an unsettled issue in the treatment of severe sepsis and septic shock. The objective of this study was to evaluate the cost-effectiveness of albumin-based resuscitation over crystalloids.

methodsA cost-effectiveness analysis was conducted by extracting data from a database of Sina Hospital, Islamic Republic of Iran. A decision tree was constructed by using Tree Age Pro 2011. The patients were grouped based on the types of fluids used for resuscitation into crystalloid alone or crystalloid + albumin groups at the initial decision node. The patients were followed from the onset of severe sepsis and septic shock upto 28 days. The healthcare payers' perspective was considered in constructing the model. The cost was measured in US dollars and the effectiveness was measured by life years gained.

resultsThe addition of albumin during resuscitation of patients with severe sepsis and septic shock has an effectiveness gain of 0.09 life years and cost increment of 495.00 USD. The estimated ICER for this analysis was 5500.00 USD per life year gained. The probability that albumin is cost-effective at one GDP per capita is 49.5%.

conclusionAlbumin-based resuscitation is not cost-effective in Iran when a GDP per capita was considered for a life year gain. The cost-effectiveness was insensitive to the cost of standard care. We recomend the caustious use albumin as per the Surviving Sepsis Campaign guideline.

Indexed as

AlbuminsCost-Benefit AnalysisFemaleFluid TherapyHumansIranMaleMiddle AgedResuscitationRetrospective StudiesSepsisShock, SepticTreatment OutcomeAlbuminsAlbumincost-effectivenesscrystalloidseconomicevaluation

Identifiers

PMID30700954
PMCPMC6341442
OpenAlexW2963272421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.